CSX
57
6
PNR
69
4
NTAP
66
2
PCAR
56
3
ZTS
49
2
COST
63
5
CMCSA
52
4
PLD
48
-5
CAH
53
6
AA
60
9
MMC
60
6
MTCH
42
5
CINF
51
4
SLG
66
2
HOG
33
4
ROP
59
5
EQR
59
5
SWK
61
5
HSIC
51
-3
HP
45
4
CSX
57
6
PNR
69
4
NTAP
66
2
PCAR
56
3
ZTS
49
2
COST
63
5
CMCSA
52
4
PLD
48
-5
CAH
53
6
AA
60
9
MMC
60
6
MTCH
42
5
CINF
51
4
SLG
66
2
HOG
33
4
ROP
59
5
EQR
59
5
SWK
61
5
HSIC
51
-3
HP
45
4
Financhill
Back

Sangamo Therapeutics 10K Form

Sell
49

SGMO
Sangamo Therapeutics

Last Price:
1.95
Seasonality Move:
29.11%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SGMO News And Ratings

See the #1 stock for the next 7 days that we like better than SGMO

SGMO Financial Statistics

Sales & Book Value

Annual Sales: $176.23M
Cash Flow: $11.64M
Price / Cash Flow: 0
Annual Sales: $0.19
Price / Book: 10.45

Profitability

EPS (TTM): -0.75000
Net Income (TTM): $-134.84M
Gross Margin: $0
Return on Equity: -199.86%
Return on Assets: -93.87%

Sangamo Therapeutics Earnings Forecast

Key Sangamo Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 18 years for SGMO is 0.00%.
  • The Selling, General & Administrative Expenses for SGMO have been equal to 34.71% of Gross Profit Margin.
  • The Research & Development expenses have been 132.81% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of SGMO is -146.30% of Total Revenues.
  • Per Share Earnings over the last 28 years have been positive in 7 years.

Sangamo Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: SGMO
CUSIP: 800677
Website: sangamo.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 1.35
Quick Ratio: 1.15

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

SGMO Technical Analysis vs Fundamental Analysis

Sell
49
Sangamo Therapeutics (SGMO) is a Sell

Is Sangamo Therapeutics a Buy or a Sell?